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Abstract
Background: The novel hormonal drugs have recently entered in the armamentarium of therapies for treatment of metastatic
castration-resistant prostate cancer (CRPC). First reports are available for their use in elderly men with CRPC.
Method: A meta-analysis of randomized controlled trials (RCTs) has been performed. PubMed, the Cochrane Library, and
American Society of Clinical Oncology (ASCO) University Meeting were searched for data on the use of new hormonal treatment in
elderly patients with CRPC.
Results:Nine studies for a total of 3512 elderly patients were available for meta-analysis. Six studies reported outcomes of patients
aged>75 years old while 2 studies reported on patients aged>70 years old. The pooled analysis of the androgen synthesis inhibitors
revealed signiﬁcantly increased overall survival (OS) due to antiandrogen agents compared with placebo or placebo and prednisone
(hazard ratio (HR) for death: HR=0.74, 95% CI: 0.67–0.82; P<0.00001). Moreover, the new antiandrogenic therapy signiﬁcantly
improved the progression-free survival (HR=0.45, 95% CI: 0.31–0.65; P<0.0001). The incidence of any grade ≥3 adverse effect
was only moderately higher during with the antiandrogenic therapy as compared to the control arms (response rate=1.03, 95% CI:
0.88–1.20; P=0.72).
Conclusion: This study conﬁrmed that agents targeting the androgen axis (i.e., enzalutamide, abiraterone) signiﬁcantly prolonged
OS in elderly men with CRPC.
Abbreviations: ASCO = American Society of Clinical Oncology, CRPC = castration-resistant prostate cancer, FDA = Food and
Drug Administration, HR = hazard ratio, OS = overall survival, PFS = progression-free survival, PSA = prostatic antigen speciﬁc,
RCTs = randomized controlled trials, RR = relative risk.
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1. Introduction 75 years.[1,2] These elderly patients are often fragile with severalProstate cancer can be considered as a disease of the elderly
since, it was estimated that the 35% of cases were diagnosed
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1comorbidities, therefore they could have a low tolerability to
antitumoral treatments, especially if chemotherapy-based agents.
The adequate management of the disease represents also an
emerging issue due to the recent availability of new effective
agents for the treatment of metastatic castration resistant prostate
cancer (CRPC) in either chemotherapy naïve men or chemo-
therapy refractory,[3] and many patients do not receive optimal
therapy as the result of treatment decisions made primarily on the
basis of chronological age alone. In this scenario, unfortunately
the current guidelines do not make speciﬁc recommendations for
the treatment of elderly men with prostate cancer. Therefore,
there is a clinical need for speciﬁc data on elderly patients with
CRPC exposed to the new drugs. Abiraterone and enzalutamide
are 2 novel agents targeting the androgen axis, both approved for
CRPC treatment,[4–7] while abiraterone targets a pivotal enzyme
for CRPC progression such as the CYP17 enzymes, enzalutamide
is a novel potent androgen receptor signaling antagonist.
Additionally, orteronel (TAK-700) is a nonsteroidal, reversible,
selective 17,20-lyase inhibitor demonstrating some activity in
CRPC patients.[8,9] First clinical reports suggest these new
hormonal agents improved outcomes in both younger and older
men, with comparable safety and tolerability.[10,11] The nature of
these studies, mostly post hoc analyses, does not allow deﬁnitive
conclusions on the real effects of all these novel hormonal
therapies in the elderly CRPC population. Therefore, the aim of
this study is to evaluate and analyze the clinical data from
Figure 1. Trial selection ﬂow chart.
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new antiandrogenic drugs in elderly patients (over 75 years old)
with CRPC.
2. Materials and methods
2.1. Data retrieval strategies
We conducted this meta-analysis of randomized controlled trials
(RCTs) in accordance with the preferences for reported items in
systematic reviews and meta-analyses guidelines.[12] PubMed/
MEDLINE, the Cochrane Library, and American Society of
Clinical Oncology (ASCO) University Meeting were searched for
relevant publications using the following terms: “prostate
cancer,” “castration-resistant prostate cancer,” “CRPC,” “el-
derly” and “abiraterone,” “enzalutamide,” “orteronel,” “ARN-
509,” “Galeterone,” and “ODM-201.” The publications that
were available in these databases up to April 1, 2016, were
analyzed. The search was restricted to human studies. The search
criteria were limited to phase III or phase II RCTs. The computer
search was supplemented with manual searches of the references
listed in all of the retrieved review articles, primary studies.
2.2. Inclusion criteria
Two independent reviewers screened the studies according to
speciﬁc selection and exclusion criteria. The inclusion/exclusion
decisions regarding contentious studiesweremadevia consultation
with a third reviewer. The studies were identiﬁed according to the
following inclusion criteria: elderly human participants with
CRPC; a new antiandrogenic drug interventions; the presence of a
control for comparison (placebo or not), a primary outcome of
survival expressed as the hazard ratio (HR) and secondary
outcomes of progression-free survival (PFS) expressed asHR, time
to prostatic antigen speciﬁc (PSA) progression expressed as HR,
PSA response rate expressed as relative risk (RR), and major
adverse effects (any grade 3–4 adverse event) expressed as RR. The
following exclusion criteria were used: insufﬁcient data were
available to estimate the outcomes; animal studies; the size of each
arm was fewer than 10 participants; the presence of a single arm
study, and studies conducted before 2010.
2.3. Data extraction
Two authors independently extracted the relevant data including
the name of the ﬁrst author, country, publication year, character-
istics of the enrolled patients (i.e., age, number, and drug
administration), median follow-up, median treatment duration,
and information about the study design (i.e., the type of blinding,
the type of control, the methods for randomization allocation),
survival outcomes expressed as HRs for overall survival (OS) and
PFS and time to PSA progression, number of patients who
experienced a PSA response of the 50% and any adverse major
event (grade 3–4). For each trial, the new hormonal agent±
prednisone was considered to be the experimental arm.
2.4. Quality assessment
The methodological quality of each included RCT was assessed
by 2 independent researchers (DS and RC). Study quality was
assessed using the Jadad 5-item scale, taking into account
randomization, double blinding, and withdrawals. The ﬁnal
score ranged from 0 to 5.[13] Disagreements were evaluated by a
kappa test and consensus was achieved in discussion with the
corresponding author (GR).22.5. Statistical analysis
The statistical analyses were performed with Revman 5.3.
The summary estimates were generated using a ﬁxed-effect
model (Mantel–Haenszel method) or a random-effect model
(DerSimonian–Laird method)[14,15] depending on the absence or
presence of heterogeneity. Statistical heterogeneity was assessed
with theQ test and the I2 statistic. I2 valuesof25%,50%,and75%
were considered to indicate low,moderate, andhighheterogeneity,
respectively.[16] When P>0.1 and I2<50%, the ﬁxed-effects
model was used; otherwise, the random-effects model was used.
For the time-to-event variables, including OS, PFS, time to PSA
progression, and time to ﬁrst skeletal even, the HRs with the 95%
conﬁdence intervals (95%CIs) were calculated for each study. For
the dichotomous variables, including PSA response and the rate of
adverse events, the RRs with the 95%CIs were calculated for each
study. Due to the small number of trial that were included,
no publication bias was estimated. A subgroup analysis was
performed to highlight any differences between studies in pre- and
postdocetaxel settings for all end points. For all the statistical
analyses, a value of P<0.05 was regarded as statistically
signiﬁcant, and all tests were 2-sided. Ethical approval was
obtained from the ethics committee of the University of Brescia.3. Results
3.1. Literature review and characteristics of the included
studies
Nine studies[8–11,17–21] with 1970 cases in the antiandrogenic
group and 1542 cases in the control group were included in the
meta-analysis according to the inclusion and exclusion criteria
described in the Materials and Methods Section (Fig. 1). Six
[10,11,17–20]
Table 1
Characteristics of the included studies.
Trials Treatment arms Cases ≥75 years Primary endpoints Jadad score
AFFIRM Enzalutamide vs placebo 199; 104 Overall survival 5
COU-AA-301 Abiraterone+prednisone vs placebo+prednisone 220; 111 Overall survival 5
COU-AA-302 Abiraterone+prednisone vs placebo+prednisone 185; 165 Radiographic progression-free survival and overall survival 5
ELM-PC 4 Orteronel+prednisone vs placebo+prednisone 453
∗
; 470
∗
Radiographic progression-free survival and overall survival 5
ELM-PC 5 Orteronel+prednisone vs placebo+prednisone 367
∗
; 194
∗
Overall survival 5
PREVAIL Enzalutamide vs placebo 317; 292 Radiographic progression-free survival and overall survival 5
TERRAIN Enzalutamide vs bicalutamide 54; 64 Progression-free survival 4
STRIVE Enzalutamide vs bicalutamide 77; 97 Progression-free survival 4
Sun et al Abiraterone+prednisone vs placebo 98†; 45† Time to PSA progression 5
PSA=prostatic antigen speciﬁc.
∗
Patients over 70 years old.
† Patients over 65 years old.
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studies[8,9] reported data on a subgroup analysis and regarded
>70 years old men, one trial reported data on ≥65 years old
men.[21] There were 5 postchemotherapy studies that included
1487 cases (917 in the experimental arm and 570 as control arm)
and 4 prechemotherapy studies that included 2025 cases (1053 in
the experimental arm and 972 as control arm). The patient’s
characteristics were obtained for all studies. With regard to
abiraterone, data has been obtained from 2 post hoc analysis of
the COU-AA-301 and COU-AA-302 trial respectively[10,18] and
a subgroup analysis.[21] With regard to enzalutamide, data have
been obtained from a post hoc analysis of the AFFIRM and
PREVAIL trials and from a subgroup analysis of TERRAIN and
STRIVE trials.[11,17,19,20] Finally, for orteronel data were
obtained from a subgroup analysis of ELM-PC 4, ELM-PC 5
studies. The characteristics of the studies included in the meta-
analysis and their primary end-points are summarized in Table 1.
The median Jadad score was 5. All the considered studies
were randomized. In 4 studies (COU-AA-301, COU-AA-302,
ELM-PC 4, ELM-PC 5, Sun et al) the comparator was placebo
plus prednisone, while AFFIRM and PREVAIL compared
enzalutamide over placebo, ﬁnally in TERRAIN and STRIVE
the comparator was bicalutamide.Table 2
Data on overall survival, median treatment duration, and median foll
Study Median OS, mo Median PFS, mo
AFFIRM
E vs PL 18.2 vs 13.3; HR: 0.61 9.9 vs 2.8; HR: 0.4
COU-AA-301
AA+P vs PL+P 15.6 vs 9.3; HR: 0.64 6.6 vs 5.4; HR: 0.6
COU-AA-302
AA+P vs PL+PR 28.6 vs 25.6; HR: 0.71 14.9 vs 8.3
ELM-PC 4
O+P vs PL+P 29.4 vs 27.8; HR: 0.89 HR: 0.63; 13.8 vs 8.7; H
ELM-PC 5
O+P vs PL+P 15.4 vs 13.1; HR: 0.82 8.3 vs 6.2; HR: 0.7
PREVAIL
E vs PL 32.4 vs 25.1; HR: 0.61 Not reached vs 3.7; HR:
TERRAIN
E vs BIC NR 11.8 vs 5.1; HR: 0.5
STRIVE
E vs BIC NR 16.7 vs 5.6; HR: 0.2
Sun et al
AA+P vs PL+P NR NR
A= abiraterone, BIC=bicalutamide, E= enzalutamide, HR=hazard ratio, mo=months, NR=not report
33.2. Survival and other end-points
Data about OS and PFS are reported in Table 2. With regard to
the mean treatment duration, we observed 11.6 months in the
experimental group and 6.5 months in the control group and the
AFFIRM trial does not report data on treatment drug duration.
An OS higher in the experimental arm has been observed for all
the included studies. However, in studies based on the use of
orteronel in CRPC, this superiority was not statistically
signiﬁcant.
The pooled analysis revealed that the new antiandrogenic
therapy signiﬁcantly improved the OS (HR=0.74, 95% CI:
0.67–0.82; P<0.00001; Fig. 2) compared with the placebo or
placebowith prednisone. The ﬁxed-effects model was used for the
analysis of the OSs. In the subgroups analysis of the
antiandrogenic combinations used in the pre- and postchemo-
therapy settings, the results revealed that the therapies with
antiandrogenic agents signiﬁcantly improved the OS to a greater
extent in the postchemotherapy setting (HR=0.71, 95% CI:
0.61–0.84) than in the prechemotherapy setting (HR=0.76,
95% CI: 0.66–0.87) (Fig. 2). However, the test for evaluating the
differences within the subgroup was not statistically signiﬁcant.
Progression-free survival (PFS) was always higher in the
experimental arm versus the control arm (Table 2). The pooledow-up of the included studies.
Median treatment duration, mo Median follow-up, mo
5 NR 14.4
6 AA: 8; PL: 4 20.2
AA: 13.8; PL: 8.3 49.2
R: 0.73 O: 10.1; PL:8.9 20.7
5 O: 6.2; PL: 5 10.7
0.17 E: 16.6; PL: 5 31
5 E: 11.7; BIC: 5.8 E: 20; BIC: 16.7
7 E: 14.7; BIC: 8.4 NR
NR 12.9
ed, OS= overall survival, P=prednisone, PFS=progression-free survival, PL=placebo.
Figure 2. Forest plots of hazard ratios (HRs) for overall survival (OS) comparing new antiandrogenic therapies to control arm. The Chi-squared test showed
moderate heterogeneity between the trials. The random effects model was used.
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improved PFS (HR=0.45, 95% CI: 0.31–0.65; P<0.0001)
(Fig. 3) compared with control (tau2=0.25). The random-effects
model was used for the analysis of the PFSs due to the presence of
high heterogeneity (I2=93%) between the trials. Regarding the
other secondary end-points, time to PSA progression and PSA
response rate for elderly patients were reported in Supplementary
Data Figs. 1 and 2, http://links.lww.com/MD/B364. However, no
statistically signiﬁcant difference has been observed. Finally,
adverse events were obtained from COU-AA-301, AFFIRM, and
PREVAIL trial. The pooled analysis with a random-effects modelFigure 3. Forest plots of hazard ratios (HRs) for progression-free survival (PFS) c
showed high heterogeneity between the trials. The random effects model was u
4also revealed the incidence of any grade ≥3 adverse effect was
only moderately higher during with the antiandrogenic therapy
(RR=1.03, 95% CI: 0.88–1.20; P=0.72; tau2=0.01; Fig. 4)
than in the control arms even if this difference was not statistically
signiﬁcant.
4. Discussion
The present study is a systematic review and a meta-analysis of
RCTs to assess the efﬁcacy and safety of new antiandrogen
therapies in elderly patients with CRPC. The new antiandrogensomparing new antiandrogenic therapies to control arm. The Chi-squared test
sed.
Figure 4. Forest plots of relative risk (RR) for any grade ≥3 adverse effect comparing new antiandrogenic therapies to control arm. The Chi-squared test showed
moderate heterogeneity between the trials. The random effects model was used.
Roviello et al. Medicine (2016) 95:43 www.md-journal.comimproved the PFS and OS of the elderly patients (mostly >75
years) with CRPC compared with control arm. Therefore, we
conﬁrm that targeting the androgenic pathway is efﬁcacious and
safe also in the subgroup of elderly CRPC.
Prostate cancer predominantly affects oldermenwith amedian
age at diagnosis of 68 years and is considered the most prevalent
cancer in men over 70 years.[22] Unfortunately, although the role
of new antiandrogen therapies in CRPC is well established,[23]
the randomized clinical trials usually have strictly inclusion
criteria, especially in regard to concomitant disease and
comorbidities, limiting the possible enrolment of elderly patients.
Moreover, guidelines make no speciﬁc recommendations to
prostate cancer patient with ages over 70. Noteworthy, older
patients are also more likely to present with very advanced
disease with a greater risk of death resulting from prostate cancer
despite from competing causes.[2] In fact it was shown that,
elderly men aged >75 years contributed almost half (48%) of all
metastatic cases.[2] In addition, several studies showed the
different risk in mortality and nonreceipt of curative treatment
for elderly prostate cancer compared to younger. In fact, the
Canadian Cancer Registry reported an higher mortality of
prostate cancer in older men compared with younger men.[24]
Unfortunately, data from a population-based study of 5456
patients have shown that men aged 70 to 79 years had a
signiﬁcant ﬁvefold increased risk of not receiving curative
treatment relative to men aged 60 to 69 years.[25] All these facts
highlight the importance of data about the use of systemic
treatments in elderly CRPC taking also into account the high
budget impact of the upcoming novel drugs with diverse
mechanisms of action for CRPC.[26]
Although, the ﬁrst reports suggest the efﬁcacy and safety
of new antiandrogen therapies in elderly patients with
CRPC,[10,11,17,18] on the other hand, the last data were derived
from a post hoc analysis of clinical randomized trials, therefore,
they require caution with further evaluations. In clinical setting,
some studies[27,28] investigated abiraterone acetate in very elderly
patients (octogenarians or ≥85 years aged patients). They have
been generated from small, retrospective studies not allowing
deﬁnitive conclusions. To best of our knowledge, this is the ﬁrst
meta-analysis of more than 3000 patients which support the use
of new antiandrogenic therapies in elderly CRPC. In regard to the
efﬁcacy end-point, such as OS and PFS, we showed their
signiﬁcant increase due to novel antiandrogen agents compared
with placebo, placebo and prednisone and bicalutamide (HR:
0.74 and 0.45, respectively). The success of these novel drugs has
reinforced the role of the androgen receptor pathway in the
progression of CRPC, highlighting the crucial role of androgens
even in patients who have met the criteria of castration resistance.5However, the optimum sequence of new agents in CRPC patients
is still unclear.[29–33] In the near future, more speciﬁed trials on
the best sequence of treatment are awaited to make deﬁnitive
conclusions in both elderly and younger patients.
It should underline that elderly men with metastatic CRPC
cannot tolerate chemotherapy-induced toxicities such as neutro-
penia, anemia, and mucositis[34] and to avoid this last adverse
event in men aged >75 years, a prophylactic use of G-CSF,
especially at cycle 1 could be undertaken. In this contest, our data
conﬁrm the good safety proﬁle of novel hormonal agents in
CRPC. The pooled analysis with a random-effects model revealed
that the incidence of any grade ≥3 adverse effect was only
moderately higher during with the antiandrogenic therapy
(RR=1.03). This is an important issue as particular attention
should be paid to the use of new agents in the elderly population
usually suffering of a number of concomitant diseases. However,
more recently several studies showed a relative safety during
novel antiandrogenic-based treatments.[35–39] First of all, the risk
of special adverse events related to CYP-17 inhibitor was never
more than 10%.[35] In addition, the long-term treatment with
this low-dose corticosteroid that is indispensable to avoid
toxicity from abiraterone is safe and tolerable in also elderly
patients.[36–38] Finally, a recent meta-analysis showed the RR of
cardiovascular events in metastatic CRPC patients treated with
abiraterone, enzalutamide, or orteronel, is signiﬁcant increased,
however the occurrence of all and grade 3–4 events is very low
(about 10%).[39]
Nonetheless, this meta-analysis has a few limitations. Data
were collected from 4 post hoc analyses; and 4 subgroup analyses
of only 7 studies, and these studies exhibited very high levels
of heterogeneity for some of the end-points. In addition, the
ELM-PC 4 and ELM-PC 5 studies reported data on patients with
>70 years of age and not 75 such as the other 4 studies. In the
subgroups of the prechemotherapy trials, the studies involved
patients who were asymptomatic or mildly symptomatic (COU-
AA-302) and only exhibited bone metastases and patients with
visceral disease (PREVAIL, ELM-PC 4, and TERRAIN), while
the STRIVE trial included also patients without metastatic
disease. It should be noted that: the abiraterone and orteronel
trials has been comparator to prednisone, whereas placebo were
used in the enzalutamide trials except for bicalutamide in
TERRAIN and STRIVE; the investigation of the adverse events
was limited to number of patients with at least one grade 3–4
event; different versions of CTCAE has been adopted in the trial;
speciﬁc toxicity data such falls, cognitive impairment, fatigue are
lacking; our analysis was based on the literature rather than on
individual patients’ data. All these elements could have been
affected the deﬁnitive results of the analysis.
[19] Shore ND, Chowdhury S, Villers A, et al. Efﬁcacy and safety of
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In conclusion, our meta-analysis supports the evidence in favor of
targeting the androgenic pathway with these novel agents in
elderly men with a relative safety proﬁle. In this contest, our
analysis which involved patients aged >70 years old and aged
>75 years in 4 studies support the use of new hormonal therapies
in over 70 years old men.References
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